Overview
HistoWiz provides automated histopathology services for researchers in academia, biotech, and pharma. Clients mail formalin-fixed tissue, and HistoWiz handles tissue processing, embedding, sectioning, and staining with automated workflows, delivering high-resolution whole-slide images in 48 hours on PathologyMap, a cloud platform for viewing, analyzing, and sharing results. The platform also supports AI-driven analysis and offers on-demand consultations with over 100 board-certified pathologists, with data stored in a large preclinical pathology database for mining. The goal is to streamline preclinical histology workflows, speed up drug discovery and research, and enable researchers to access and share digital pathology data efficiently.
Work here?Claim your company
Simplify's take
What believers are saying
- June 2024 PathologyMap 2.0 added one-click AI quality control and tissue segmentation.
- October 2024 GLP services broadened HistoWiz into regulated studies and higher-value workflows.
- 2026 careers listings and partner pages show active commercial momentum and continued customer demand.
What critics are saying
- HistoWiz still depends on service revenue from a narrow preclinical research niche.
- Current openings show sales and lab hiring, signaling execution pressure after expansion.
- If PathologyMap monetization stalls, larger lab networks and software vendors can compress margins.
What makes HistoWiz unique
- PathologyMap 2.0 launched June 27, 2024 with AI slide search and analysis.
- HistoWiz couples automated histology with digital block management and live whole-slide access.
- Its 2025 partner network includes Protege and PathologyOutlines.com, strengthening research distribution.
Help us improve and share your feedback! Did you find this helpful?
Funding
Industry standards